Introducing Lessons Learned, STAT Plus’ new weekly column on careers in biomedicine. If you’re thinking of jumping from academics to industry/business or vice versa, join us each week for useful tips. 

Who we talked to:

Max Salick, 32, postdoctoral scholar, Novartis Institutes for BioMedical Research. Organoid builder. 2017 STAT Wunderkind. Friend of canines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • So cute to think the guy was going to get a professorship by default.
    More like, my academic career is not going anywhere. Let me get out of here!
    Also because, he had only one first author publication, and a lot of coauthorships. That, especially when happening during a PhD, always stink a lot of inflated publication record. LOL

  • This is an Advertorial, another example of how Pharma is continuously misleading the public. These types of advertising and public relations pieces really should be labeled, instead healthcare professionals, policy makers and the general public are being effectively brainwashed. These unethical corporations are spending a lot of money on garbage like this placed conspicuously in formerly credible sites, and mass media.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy